Review
Common Polymorphisms in the Glycoproteins of Human Cytomegalovirus and Associated Strain-Specific Immunity

Hsuan-Yuan Wang 1,2, Sarah M. Valencia 2, Susanne P. Pfeifer 3, Jeffrey D. Jensen 3, Timothy F. Kowalik 4 and Sallie R. Permar 1,*

1 Department of Pediatrics, Weill Cornell Medicine, New York, NY 10065, USA; hsuanyuan.wang@duke.edu
2 Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA; sarah.valencia@duke.edu
3 Center for Evolution & Medicine, School of Life Sciences, Arizona State University, Tempe, AZ 85281, USA; susanne.pfeifer@asu.edu (S.P.P.); jeffrey.d.jensen@asu.edu (J.D.J.)
4 Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA 01655, USA; timothy.kowalik@umassmed.edu
* Correspondence: sap4017@med.cornell.edu; Tel.: +1-212-746-4111

Abstract: Human cytomegalovirus (HCMV), one of the most prevalent viruses across the globe, is a common cause of morbidity and mortality for immunocompromised individuals. Recent clinical observations have demonstrated that mixed strain infections are common and may lead to more severe disease progression. This clinical observation illustrates the complexity of the HCMV genome and emphasizes the importance of taking a population-level view of genotypic evolution. Here we review frequently sampled polymorphisms in the glycoproteins of HCMV, comparing the variable regions, and summarizing their corresponding geographic distributions observed to date. The related strain-specific immunity, including neutralization activity and antigen-specific cellular immunity, is also discussed. Given that these glycoproteins are common targets for vaccine design and anti-viral therapies, this observed genetic variation represents an important resource for future efforts to combat HCMV infections.

Keywords: human cytomegalovirus; glycoprotein; polymorphism; genotype; strain-specific immunity

1. Introduction
Human cytomegalovirus (HCMV) is highly prevalent, with an estimated 83% seroprevalence in the global population [1]. While HCMV-infected immunocompetent individuals are generally asymptomatic, HCMV can cause morbidity and mortality for immunocompromised individuals [2], including in the setting of organ transplant recipients, acquired immunodeficiency syndrome (AIDS), and congenital infection. Infections with multiple HCMV strains are commonly observed among these groups [3–5], and strain replacement has additionally been noted [6]. Furthermore, frequent recombination between strains continuously generates novel genotypic combinations [3]. These clinical observations indicate the interesting complexity of the population genetic environment in HCMV [4], and hence elucidating the evolutionary mechanisms dictating observed variation remains as a major research topic in the pursuit of effective vaccines and anti-viral therapies.

2. Complexity of HCMV Genomes and Viral Populations In Vivo
HCMV has long been recognized as being genetically variable. In 1980, Huang et al. observed differences in restriction fragment length polymorphisms (RFLPs) in HCMV samples cultured from congenitally infected infants [5]. Likewise, different laboratory strains were recognized, some of which were utilized in early vaccine trials [7,8]. As DNA sequencing technologies developed, entire genomes of HCMV could be delineated, highlighting nucleotide-level differences between strains on the order of ~2% [9–12]. Subsequent short
read, deep-sequencing studies confirmed genome-wide differences in HCMV consensus sequences and revealed the widespread presence of rare alleles, insertions, and deletions in patient samples [13–16]. Indeed, the significance of this within-host population-level variation in HCMV was quickly recognized [14,17–19], with nucleotide diversity approaching that of certain RNA viruses [20]. As with RNA viruses, this diversity allows for populations to be structured and varied, driven by both stochastic (e.g., infection bottleneck) and more deterministic (e.g., natural selection) evolutionary forces [15,21]. The combination of constant purifying selection and episodic positive selection, together with population size change and the related effects of genetic drift, has been found to result in a relatively high-level of neutral and weakly deleterious variation in patient samples [10]. Unlike RNA viruses however, mutation rates tend toward the more modest range of ~2 × 10−7 per site per replication [17]. Other factors contributing to the observed population-level diversity include compartmentalization and gene flow, post-infection population growth rates, recombination, and recombination [17,19,22–24]. Collectively, these features result in a collection of genetic variants in clinical specimens that may influence disease severity, responses to antiviral therapies, and vaccine candidate design.

3. Common Polymorphisms in the Glycoproteins of HCMV

The ~235 kb double-stranded DNA genome of HCMV encodes approximately 230–250 putatively functional open reading frames (ORFs) [12,17,25]. These ORFs include up to 65 unique glycoproteins [9,26], and several of them are responsible for viral attachment to and entry into the host cells. Due to their pivotal role in initiating signaling transduction cascades in target cells and propagating HCMV infection, glycoproteins have been identified as key HCMV vaccine targets. Interestingly, instead of functioning alone, glycoproteins on HCMV virions form complexes, which facilitate the pathogenesis of HCMV infection. These complexes include the glycoprotein B oligomer (gB) [27], glycoprotein M/glycoprotein N (gM/gN) dimer [28], glycoprotein H/glycoprotein L/glycoprotein O (gH/gL/gO) trimer [29], and gH/gL/gO/UL128-130 pentameric complex [30]. Table 1 summarizes the commonly observed polymorphisms in these glycoproteins, including the length and genotypes, as well as the most variable regions described to date. In order to determine the most variable regions among each glycoprotein, multiple sequence alignments were generated using T-coffee version 13.45.0.4846264 [31] (Figure S1). In addition, Table 2 presents the genotypes of several common laboratory-adapted HCMV strains, including the strains Towne, TB40E, AD169, Toledo, VR1814, and Merlin.

Table 1. Commonly observed glycoprotein polymorphic regions.

| Glycoprotein | Length (Amino Acids) | Genotypes (Subtypes) | Most Variable Region | References |
|--------------|---------------------|----------------------|----------------------|------------|
| gB (UL55)    | 907                 | gB-1, gB-2, gB-3, gB-4, gB-5 | codons 26–70, gp55 cleavage site (codon 460) | [32–34]   |
| gN (UL73)    | 135                 | gN-1, gN-2, gN-3 (gN-3a, gN-3b), gN-4 (gN-4a, gN-4b, gN-4c) | N-terminal region (codons 1–87) | [35,36]   |
| gO (UL74)    | 457–472             | gO-1 (gO-1a, gO-1b, gO-1c), gO-2 (gO-2a, gO-2b), gO-3, gO-4, gO-5 | N-terminal region (codons 1–98), codons 270–313 | [37–41]   |
| gH (UL75)    | 743                 | gH-1, gH-2            | N-terminal region (codons 1–37) | [42]       |
Table 2. Genotyping of common laboratory-adapted HCMV strains.

| Virus Strain | gB (UL55) | gN (UL73) | gO (UL74) | gH (UL75) | References |
|--------------|-----------|-----------|-----------|-----------|------------|
| Towne        | gB-1      | gN-4b     | gO-4      | gH-2      | [33,36,40,42] |
| TB40E        | gB-1      | gN-4c     | gO-1c     | gH-1      | [36,40]    |
| AD169        | gB-2      | gN-1      | gO-1a     | gH-1      | [33,36,40,42] |
| Toledo       | gB-3      | gN-4c     | gO-1c     | gH-1      | [36,38,43] |
| VR1814       | gB-3      | gN-4c     | gO-1c     | gH-1      | N/A        |
| Merlin       | gB-1      | gN-4c     | gO-3      | gH-2      | [44]       |

Genotypes were determined by multiple sequence alignment to genotype-specific reference sequences (Figure S1) using T-coffee version 13.45.0.4846264 [31]. 1 The GenBank accession numbers of published gB sequences are: TB40E strain (ABV71586.1), VR1814 strain (ACZ79984.1), and Merlin strain (AAR31620.1). 2 The GenBank accession numbers of published gN sequences are: VR1814 strain (ACZ79984.1) and Merlin strain (F5HHQ0.1). 3 The GenBank accession number of the published gO sequence is: VR1814 strain (ACZ79985.1). 4 The GenBank accession numbers of published gH sequences are: TB40E strain (ABV71597.1), VR1814 strain (ACZ79986.1), and Merlin strain (YP_081523.1).

These highly variable sites in the glycoproteins, together with viral cytokine/chemokine proteins (human cellular homologs), are commonly considered to be key factors for host immunity and HCMV infection [45]. This suggests strain-specific immunity, defined as discrete immune responses elicited by different variants of the virus genomes. Strain-specific immunity is usually classified by the strain-specific humoral and antigen-specific T-cell responses. With regards to humoral immunity, strain-specific neutralization of HCMV has been identified in human sera [46], and monoclonal antibodies isolated from both humans and rabbits have also demonstrated strain-specific recognition [47]. Strain-specific T-helper-cell response to gH has also been reported when comparing the T-cell proliferative response to antigens from strains Towne and AD169 [48]. Given that strain-specific immunity is associated with observed polymorphisms, we review these commonly variable glycoprotein sites, summarize their current geographic distributions, and present evidence relating this diversity with immune response.

4. gB

HCMV gB is the best-characterized glycoprotein to date and is encoded by UL55. Consisting of ~900 amino acids (NCBI accession number: YP_081514), gB is composed of a large ectodomain region, membrane-proximal region, transmembrane domain, and cytoplasmic domain [49]. The prototypic gB undergoes proteolytic cleavage approximately at codon 460 which generates two gB polypeptides, gp116 and gp55 (also known as gp58), that are covalently linked by disulfide bonds. While most of the gB ectodomain belongs to gp116, gp55 is a type1 transmembrane protein settled on the HCMV envelope. Required for HCMV entry into target cells and HCMV infection via cell-to-cell spread, gB is highly glycosylated and genetically variable [27]. The glycosylation sites of gB include 18 possible N-linked glycosylation sites and two O-linked glycosylation sites [50,51]. In addition, the polymorphisms within gB genotypes occur mostly around the gp55 cleavage site at codon 460 as well as, to a lesser extent, around several coding regions of gp116—an observation which has been associated with homologous recombination [32,33,52,53]. Due to the intragenic variations within the gB sequence, gB genotypes have been defined based on the variations within C-terminus, N-terminus [54–56], and the gp55 cleavage site [57] as originally proposed by Chou et al. [32]. Interestingly, samples collected at multiple body sites from the same patient can display different gB genotypes, suggesting distinct cell tropism of HCMV, consistent with the compartmentalization of viral populations observed by deep sequencing [15,17].

To date, five different gB genotypes (gB-1, gB-2, gB-3, gB-4, and gB-5 previously referred to as gB-3’ [34,58,59]) have been identified [32,33]. We here review previous research investigating the correlations between gB genotypes and clinical outcomes, focusing (by and large) on individuals with compromised immune systems (e.g., organ/bone marrow transplant recipients, AIDS patients, and congenitally or perinatally HCMV-infected infants). Figure 1 organizes the gB genotyping studies alphabetically by study continent.
and country, as well as by patient profile. All five genotypes have been detected in Asia, Europe, and North America, however their geographic distribution differs: gB-1 is the most prevalent genotype in Asia and Egypt [60–99]; gB-1 and gB-2 are frequently detected in North America [58,100–109]; gB-2 is the most extensively sampled genotype in Latin America [110–123]; whereas gB-1, gB-2, and gB-3 are commonly observed across Europe (with the exception of Serbia where gB-4 is the most prevalent genotype) [24,55,57,59,124–153]. Although the majority of HCMV-positive individuals who participated in these studies carried gB-1, gB-2, and/or gB-3 genotypes, the association between any particular gB genotype and disease severity is inconsistent among studies [24,55,59–78,83,94–100,102–112,116–142,148–154]. When a gB genotype has been identified as a disease severity marker, it was often simply the most prevalent genotype in the study population. Thus, it is currently difficult to draw a conclusion as to whether there is a specific gB genotype that leads to a more severe disease progression. Compared to a single gB genotype infection, mixed gB genotype infections are frequently reported in organ/bone marrow transplant recipients and AIDS patients [105,118,125,128,129,152]. Multiple studies have also demonstrated that mixed infections are able to be transmitted in utero [63,68,74–77,109,122,134,137,138,141]. Although there is no established association between single genotype infections and disease outcomes, patients with mixed gB genotype infections have been reported to have faster disease progression or higher viral loads [83,97,102,144]. This observation highlights the importance of targeting diverse HCMV strains in vaccine design and therapeutics.

gB has been identified as one of the major HCMV vaccine targets due to its essential role in virion fusion with the cell and ability to elicit both neutralizing [155] and non-neutralizing antibody responses [156,157]. Currently, the gB subunit protein from the Towne strain (gB-1) with MF59 adjuvant (gB/MF59) is the most effective vaccine tested to date in several phase I and II clinical trials [158–160]. gB-1, gB-2, and gB-4 share a greater genetic similarity compared to gB-3 and gB-5, having been described as comprising two “supergroups” [43]. High-throughput sequencing of viruses from infected individuals who were given either a gB/MF59 or a placebo vaccine showed that gB/MF59 vaccinees were more resistant to infection from HCMV from the gB-1, gB-2, and gB-4 genotype supergroup compared to the placebo recipients, suggesting the protective effect of the vaccine was limited to this supergroup [161]. Additionally, a single variant of gB, 275Y of AD169 strain and 585G of VR1814 strain, was shown to impact viral entry, cell fusion, and genome stability via activation of ATM (ataxia-teleangiectasia mutated)-PIDDosome-caspase-2 signaling axis. Thus, this study suggested that even a single nucleotide polymorphism of gB is critical to the pathogenesis of HCMV infection [162]. Interestingly, with 200 HCMV clinical strains analyzed, gB sequences were found to have a greater diversity among strains compared to those of the pentameric complex. This observation highlights the complexity of gB variation, even though gB genotypes exhibit a ~96% mean conserved identity at the amino acid level. This indicates the dominant action of purifying selection in gB, making it more highly conserved than other glycoproteins including gN and gO [163].
Figure 1. Global gB genotyping across disease states. gB genotyping studies are organized alphabetically by study continent and country, as well as by patient profile (TR: transplant recipient; AIDS: AIDS patient; C/PW: congenital CMV infection or pregnant woman). The percentage of each gB genotype among study participants is shown, with the most common genotypes highlighted in red, genotypes at intermediate frequency in orange, and less common genotypes in yellow. Gray cells indicate that a particular gB genotype was not identified in the reference studies. Note that the sum of all genotypes may be greater or smaller than 1 if multiple gB genotypes were identified in the same sample or if not all samples in a study were genotyped, respectively.

5. gN

HCMV gN, encoded by UL73, is a type 1 transmembrane protein that links it to gM by disulfide bonds. Although gN is only composed of ~135 amino acids (NCBI accession number: YP_081521), this protein has aroused interest of late due to its considerable post-translational modifications and high-level of polymorphism. The post-translational
modifications of gN include 18 potential phosphorylation sites, 33 possible O-linked glycosylation sites [35], and two N-linked glycosylation sites (reviewed in [164]). gN is highly variable particularly in the N-terminal region, outside virus particles, which is believed to be involved in eliciting immune responses and responding to immunological selective pressure. Based on the differences in the N-terminal region, four gN genotypes have been identified. Two subtypes of gN-3 (gN-3a, gN-3b) and three subtypes of gN-4 (gN-4a, gN-4b, gN-4c) have been further distinguished. The similarity of nucleotides within each genotype is around 80–85%, while the nucleotide similarity within each subtype is 96–100% [35,36].

Considering the geographic distribution of gN genotypes, a global study reported that clinical isolates from China, Australia, and Europe unexpectedly demonstrated a similar frequency of gN-1, gN-3, and gN-4, whereas gN-2 was infrequently detected in Europe and not identified in China and Australia. On the other hand, gN-2 is more commonly detected in North America than other regions, though when detected, gN-1, gN-3, and gN-4 remain the more prevalent [36]. However, the findings of the above global study are not entirely consistent with the local gN genotyping studies as shown in Figure 2. All four gN genotypes have been reported in Asia. However, the gN-4 genotype has often been reported as the most prevalent genotype globally, followed by gN-1 or gN-3, and gN-2. In a single study from Egypt, gN-1 was the most prevalent genotype in breast cancer patients [93].

![Figure 2](image-url)

**Figure 2.** Global gN genotyping across disease states. gN genotyping studies are organized alphabetically by study continent and country, as well as by patient profile (TR: transplant recipient; AIDS: AIDS patient; C/PW: congenital CMV infection or pregnant woman). The percentage of each gN genotype among study participants is shown, with the most common genotypes highlighted in red, genotypes at intermediate frequency in orange, and less common genotypes in yellow. Gray cells indicate that a particular gN genotype was not identified in the reference studies. Note that the sum of all genotypes may be greater or smaller than 1 if multiple gN genotypes were identified in the same sample or if not all samples in a study were genotyped, respectively.

In terms of the immune responses to gN related to observed genotypic variation, only humoral immunity has been characterized to date. These studies have mainly focused on investigating neutralizing antibody responses against four gN genotypes, and strain-specific neutralizing activity against gN strains has been demonstrated [165–167]. It has been shown that anti-gM/gN dimer antibodies possess differential neutralizing activities against AD169, Toledo, and TR strains. Since there have been no gM polymorphisms reported, this study suggested that the neutralizing anti-gM/gN dimer antibody responses against gN might be strain-specific. However, because this study did not iso-
late gN-specific antibodies and identify neutralizing epitopes lying in the most variable regions of gN, further studies are required to confirm that the neutralization against gN is strain-specific [165]. To investigate the antibody response against gN genotypes more specifically, viruses with four different gN genotypes in the same AD169 virus backbone were constructed. By creating a neutralization assay with these gN-recombinant viruses, strain-specific neutralization was measurable in 30–60% of human sera. Interestingly, human sera collected from subjects in Erlangen (Germany) appeared to neutralize the virus with gN-4 genotype the best, while the cohort from Birmingham (USA) neutralized the virus with gN-2 genotype most potently [166,167]. This observation is consistent with the geographical distribution of HCMV gN genotypes from previous studies [36].

6. gO

HCMV gO, a soluble protein encoded by UL74, is an essential element of the gH/gL/gO trimer. Compared to the pentameric complex, the gH/gL/gO trimer has been reported as an integral component of HCMV entry by promoting fusion with all cell types [168]. gO is composed of 457–472 amino acids (NCBI accession number: YP_081522.1), depending on the number of strain-specific deletions. gO is also highly glycosylated, with variation in glycosylation observed among genotypes. The glycosylation sites of gO include 18 potential N-linked glycosylation sites and a single O-linked glycosylation site [50,51]. Of the polymorphisms most commonly observed in the gO sequence, the major variable region lies in the first 98 codons, with some minor variations between codon 270–313 [37]. Based on these differences among gO sequence, four gO genotypes were identified in AIDS patient in 2002 [38], while the fifth gO genotype was verified in 2005 after detection in renal transplant recipients [39]. By tree-based analysis of HCMV sequences in lung transplant recipient samples, three subtypes of gO-1 (gO-1a, gO-1b, gO-1c), and two subtypes of gO-2 (gO-2a, gO-2b) have been reported [40,41].

Previous gO genotyping studies are organized in Figure 3. The neighbor-joining tree analysis of gO genotypes from several studies found disparate genetic similarities between gO genotypes and their subtypes [41,44,169]. In terms of geographic distribution, five gO genotypes have been detected in Asia, Europe, and Australia, with gO-5 being consistently the least frequently detected. Little correlation has been observed between genotype and disease perhaps due to a paucity of gO genotyping studies. Nonetheless, the gO-1 genotype appears to be the most prevalent in most studies [38,41,98,138,170]. Further, previous work has suggested that the gO-1b genotype is linked to gN-3a and gH-1, while the gO-5 genotype was linked to gN-4c and gH-2. However, the implications of this association, and whether it holds any clinical relevance, remains in need of further study [44].

Finally, the functional difference of gO genotypes have been investigated to some extent. Comparing HCMV reconstituted with two highly variable gO genotypes, gO-1 and gO-4, in the same TB40E backbone, the gO-4 genotype displayed an increasing tropism for epithelial cells compared to the gO-1 genotype [171]. Additionally, there was a different inhibitory effect of soluble HCMV trimer- and pentamer-specific entry receptors observed by comparing reconstituted HCMV with gO-1, gO-2, gO-3, and gO-5 genotypes in the same TB40E backbone [172]. It has also been suggested that different gO genotypes have an impact on neutralizing antibody response to gH epitopes [173].
Figure 3. Global gO genotyping across disease states. gO genotyping studies are organized alphabetically by study continent and country, as well as by patient profile (TR: transplant recipient; AIDS: AIDS patient; C/PW: congenital CMV infection or pregnant woman). The percentage of each gO genotype among study participants is shown, with the most common genotypes highlighted in red, genotypes at intermediate frequency in orange, and less common genotypes in yellow. Gray cells indicate that a particular gO genotype was not identified in the reference studies. Note that the sum of all genotypes may be greater or smaller than 1 if multiple gO genotypes were identified in the same sample or if not all samples in a study were genotyped, respectively.

7. gH

HCMV gH, encoded by UL75, has been identified as an integral component of the gH/gL/gO trimer and the pentameric complex. In addition to gB, the pentameric complex has remained a key vaccine target given that the complex is required for HCMV to enter epithelial, endothelial, and monocytic cells [30,174–176]. Belonging to type I transmembrane protein, gH is 742-amino-acids long (NCBI accession number: YP_081523.1), and compared to other glycoproteins described above, gH is moderately glycosylated and less variable. The sequence of gH has been reported to include six potential N-linked glycosylation sites and four O-linked glycosylation sites [50,51]. Based on the variability of gH sequences, the gH genotypes could be divided into two groups, gH-1 and gH-2. The variable regions between the two groups are mostly identified in the first 37 codons near the N-terminal region and minorly between codons 176–181 and 359–365 [42]. The observed geographic distribution of gH genotypes is shown in Figure 4. Moreover, gH-1 and gH-2 genotypes are distributed fairly equally in organ transplant recipients and HCMV-infected children sampled to date.

gH has been identified as one of the major antigens for eliciting neutralizing antibody responses [177,178]. In a recent study, the neutralizing ability of certain gH-specific monoclonal antibodies were shown to be strain-specific in fibroblasts and epithelial cells. The neutralizing epitopes of these antibodies lie at codons 27–48, the most variable region of gH [47]. Additionally, a previous study has compared the outcomes of renal transplant recipients who elicit matched or mismatched strain-specific gH antibody responses after kidney transplantation. The patients with mismatched anti-gH antibodies appear to have more adverse outcomes compared to those with matched anti-gH antibodies, including a higher possibility of acute tissue rejection, HCMV disease-related manifestations, and a higher level of antigenemia. This suggests that the strain-specific gH antibody may be correlated with disease severity [179]. In terms of cellular immunity, it has also been reported that the T-helper-cell response to gH is strain-specific [48].
Figure 4. Global gH genotyping across disease states. gH genotyping studies are organized alphabetically by study continent and country, as well as by patient profile (TR: transplant recipient; AIDS: AIDS patient; C/PW: congenital CMV infection or pregnant woman). The percentage of each gH genotype among study participants is shown, with the most common genotypes highlighted in red, genotypes at intermediate frequency in orange, and less common genotypes in yellow. Gray cells indicate that a particular gH genotype was not identified in the reference studies. Note that the sum of all genotypes may be greater or smaller than 1 if multiple gH genotypes were identified in the same sample or if not all samples in a study were genotyped, respectively.

8. Concluding Remarks

We have reviewed the commonly observed polymorphic sites and regions of HCMV glycoproteins (gB, gN, gO, and gH), which play an essential role in the formation of glycoprotein complexes on the surface of the HCMV virion. Additionally, we have organized data from previous global genotyping studies of HCMV glycoproteins. The dominant gB and gH genotypes across disease states in each continent are summarized in Table 3. The percentage of each genotype in the same country varies by study, and further data will be required to determine whether significant geographic statistical associations exist.

We have also reviewed the biological relevance of polymorphisms within viral glycoproteins by presenting evidence relating them with strain-specific immune responses. The biological relevance of specific genotypic variation has been suggested by several studies. For example, gH neutralizing epitopes were shown to lie in the most variable regions of gH [47], suggesting that the polymorphisms of glycoproteins might be an effective strategy for virus immune evasion. Additionally, instead of directly mediating neutralizing antibody responses, the polymorphisms of glycoproteins could indirectly moderate neutralizing antibody responses by blocking neutralizing epitopes of other glycoproteins. For example, it has been reported that polymorphisms within gO protected neutralizing epitopes of gH [173]. In terms of strain-specific T-cell immunity, there are currently no studies at the individual epitope level relating to glycoprotein variation, though one study
has reported that T-helper cell response to gH is strain-specific [48]. Further studies are required to fully understand the functional relevance of such glycoprotein variability.

Table 3. Dominant gB and gH genotypes across disease states in each continent.

| Continent        | Dominant gB Genotype ¹ | References | Dominant gH Genotype ¹ | References |
|------------------|------------------------|------------|------------------------|------------|
| Asia             | gB-1, gB-2             | [60,61,72,83,94–97] | gH-1                   | [72,79,95] |
| Europe           | gB-1, gB-2             | [124–126,149–153] | gH-1, gH-2             | [124,152]  |
| North America    | gB-1                   | [100,102–105,148]| gH-1, gH-2             | [148]      |
| Latin America    | gB-1, gB-2             | [110,111,116–119] |                        |            |
| Oceania          | N/A                    |            | N/A                    |            |

AIDS patient

| Continent        | Dominant gB Genotype ¹ | References |
|------------------|------------------------|------------|
| Asia             | gB-1                   | [98]       |
| Europe           | gB-2                   | [59,127–130]|
| North America    | gB-2                   | [106,107]  |
| Latin America    | gB-1, gB-2, gB-3       | [120,121]  |
| Oceania          | gB-1, gB-2, gB-4       | [154]      |

Congenital CMV infection or pregnant woman

| Continent        | Dominant gB Genotype ¹ | References |
|------------------|------------------------|------------|
| Asia             | gB-1                   | [62–71,73–78,99] | gH-1 | [66,73,78,138,180,181] |
| Europe           | gB-1                   | [24,55,131–142,152] | gH-1, gH-2 | [55,133,142,152,182,183] |
| North America    | gB-1, gB-2             | [108,109]  | gH-1, gH-2             | [109]      |
| Latin America    | gB-2                   | [112,122,123] |                        |            |
| Oceania          | gB-1                   | [154]      |

¹ The dominant gB or gH genotype was determined by identifying the most common gB or gH genotype across all referenced studies.

Although considerable data have been accumulated in recent years, many important questions still remain regarding how common polymorphisms in glycoproteins should best be incorporated into CMV vaccine development. Specifically, the nature and degree of associations between genotypic variation in the glycoproteins and functional difference in HCMV, as well as the elicited strain-specific immunity by genotype, should be further studied in relation to protection against CMV acquisition and reinfection. Although the situation is further complicated by the prevalence of mixed-strain infections, the relationship between these mixed infection and disease severity and progression is of growing interest. These emerging results suggest the importance of multivalent vaccine designs, as well as a consideration of glycoprotein variation in future HCMV vaccine design and therapy.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/v13061106/s1. Figure S1: Peptide sequence variations that define: (a) five gB genotypes, (b) four gN genotypes, (c) five gO genotypes, and (d) two gH genotypes.

Funding: This research was funded by NIH-NIAID, grant number 5P01AI129859, Immunologic and virologic determinants of congenital Cytomegalovirus transmission and disease in rhesus monkeys.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.
**Data Availability Statement:** Not applicable.

**Acknowledgments:** The sequence alignment figures in Figures 1–4 are made by BOXSHADE Server (https://embnet.vital-it.ch/software/BOX_form.html, accessed on May–June 2021).

**Conflicts of Interest:** S.R.P. is a consultant for Merck, Moderna, and Dynavax vaccine programs. S.M.V. has a sponsored research program with Merck and Moderna. T.F.K. is a consultant to the Moderna vaccine program. All the other authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

**References**

1. Zuhair, M.; Smit, G.S.A.; Wallis, G.; Jabbar, F.; Smith, C.; Devleesschauwer, B.; Griffiths, P. Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis. *Rev. Med. Virol.* 2019, 29, 1–6. [CrossRef]

2. Emery, V.C. Investigation of CMV disease in immunocompromised patients. *J. Clin. Pathol.* 2001, 54, 84–88. [CrossRef] [PubMed]

3. Chou, S.W. Reactivation and recombination of multiple cytomegalovirus strains from individual organ donors. *J. Infect. Dis.* 1989, 160, 11–15. [CrossRef] [PubMed]

4. Sackman, A.M.; Pfeifer, S.P.; Kowalik, T.F.; Jensen, J.D. On the demographic and selective forces shaping patterns of human cytomegalovirus variation within hosts. *Pathogens* 2018, 7, 16. [CrossRef]

5. Huang, E.S.; Huang, S.M.; Tegtmeier, G.E.; Alford, C. Cytomegalovirus: Genetic variation of viral genomes. *Ann. N. Y. Acad. Sci.* 1980, 354, 332–346. [CrossRef] [PubMed]

6. Rasmussen, L.; Geissler, A.; Winters, M. Inter- and Intragenic Variations Complicate the Molecular Epidemiology of Human Cytomegalovirus. *J. Infect. Dis.* 2003, 187, 809–819. [CrossRef]

7. Plotkin, S.A.; Furukawa, T.; Zygrich, N.; Huygelen, C. Candidate cytomegalovirus strain for human vaccination. *Infect. Immun.* 1975, 12, 521–527. [CrossRef]

8. Plotkin, S.A.; Friedman, H.M.; Fleisher, G.R.; Dafoe, D.C.; Grossman, R.A.; Lynn Smiley, M.; Starr, S.E.; Wlodaver, C.; Friedman, A.D.; Barker, C.F. Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants. *Lancet* 1984, 323, 528–530. [CrossRef]

9. Chee, M.S.; Bankier, A.T.; Beck, S.; Bohni, R.; Brown, C.M.; Cerny, R.; Horsnell, T.; Hutchison, C.A.; Kouzarides, T.; Martignetti, J.A.; et al. Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. In *Proceedings of the Cytomegaloviruses*; McDougall, J.K., Ed.; Springer: Berlin/Heidelberg, Germany, 1990; pp. 125–169.

10. Renzette, N.; Pfeifer, S.P.; Matuszewski, S.; Kowalik, T.F.; Jensen, J.D. On the analysis of intrahost and interhost viral populations: Human cytomegalovirus as a case study of pitfalls and expectations. *J. Virol.* 2017, 91, 1–8. [CrossRef]

11. Sinzger, C.; Hahn, G.; Digel, M.; Katona, R.; Sampaio, K.L.; Messerle, M.; Hengel, H.; Koszinowski, U.; Brune, W.; Adler, B. Cloning and sequencing of a highly productive, endotheliotropic virus strain derived from human cytomegalovirus TB40/E. *J. Gen. Virol.* 2008, 89, 359–368. [CrossRef]

12. Murphy, E.; Yu, D.; Grimwood, J.; Schmutz, J.; Dickson, M.; Jarvis, M.A.; Hahn, G.; Nelson, J.A.; Myers, R.M.; Shenk, T.E. Coding potential of laboratory and clinical strains of human cytomegalovirus. *Proc. Natl. Acad. Sci. USA* 2003, 100, 14976–14981. [CrossRef] [PubMed]

13. Cunningham, C.; Gatherer, D.; Hilfrich, B.; Baluchova, K.; Daragan, D.J.; Thomson, M.; Griffiths, P.D.; Wilkinson, G.W.G.; Schulz, T.F.; Davison, J.A. Sequences of complete human cytomegalovirus genomes from infected cell cultures and clinical specimens. *J. Gen. Virol.* 2010, 91, 605–615. [CrossRef] [PubMed]

14. Renzette, N.; Bhattacharjee, B.; Jensen, J.D.; Gibson, L.; Kowalik, T.F. Extensive genome-wide variability of human cytomegalovirus in congenitally infected infants. *PLoS Pathog.* 2011, 7, e1001344. [CrossRef] [PubMed]

15. Renzette, N.; Gibson, L.; Bhattacharjee, B.; Fisher, D.; Schleiss, M.R.; Jensen, J.D.; Kowalik, T.F. Rapid intrahost evolution of human cytomegalovirus is shaped by demography and positive selection. *PLoS Genet.* 2013, 9, e1003735. [CrossRef]

16. Sijmons, S.; Thyss, K.; Corthout, M.; Van Damme, E.; Van Loock, M.; Bollen, S.; Baguet, S.; Aerssens, J.; Van Ranst, M.; Maes, P. A method enabling high-throughput sequencing of human cytomegalovirus complete genomes from clinical isolates. *PLoS ONE* 2014, 9, e95501. [CrossRef]

17. Renzette, N.; Pokalyuk, C.; Gibson, L.; Bhattacharjee, B.; Schleiss, M.R.; Hamprecht, K.; Yamamoto, A.Y.; Mussi-Pinhata, M.M.; Britt, W.J.; Jensen, J.D.; et al. Limits and patterns of cytomegalovirus genomic diversity in humans. *Proc. Natl. Acad. Sci. USA* 2015, 112, E4120–E4128. [CrossRef] [PubMed]

18. Suárez, N.M.; Wilkie, G.S.; Hage, E.; Camilo, S.; Holton, M.; Hughes, J.; Maabar, M.; Vattipally, S.B.; Dhingra, A.; Gompels, U.A.; et al. Human cytomegalovirus genomes sequenced directly from clinical material: Variation, multiple-strain infection, recombination, and gene loss. *J. Infect. Dis.* 2019, 220, 781–791. [CrossRef]

19. Cudini, J.; Roy, S.; Houldcroft, C.J.; Bryant, J.M.; Depledge, D.P.; Tuttill, H.; Vey, P.; Williams, R.; Worth, A.J.J.; Tamuri, A.U.; et al. Human cytomegalovirus haplotype reconstruction reveals high diversity due to superinfection and evidence of within-host recombination. *Proc. Natl. Acad. Sci. USA* 2019, 116, 5693–5698. [CrossRef]

20. Renzette, N.; Gibson, L.; Jensen, J.D.; Kowalik, T.F. Human cytomegalovirus intrahost evolution—A new avenue for understanding and controlling herpesvirus infections. *Curr. Opin. Virol.* 2014, 8, 109–115. [CrossRef]
21. Renzette, N.; Kowalik, T.F.; Jensen, J.D. On the relative roles of background selection and genetic hitchhiking in shaping human cytomegalovirus genetic diversity. *Mol. Ecol.* 2016, 25, 403–413. [CrossRef]

22. Yamamoto, A.Y.; Mussi-Pinhata, M.M.; Boppana, S.B.; Novak, Z.; Wagatsuma, V.M.; de Frizzo Oliveira, P.; Duarte, G.; Britt, W.J. Human cytomegalovirus reinfection is associated with intrauterine transmission in a highly cytomegalovirus-immune maternal population. *Am. J. Obstet. Gynecol.* 2010, 202, 297.e1–297.e8. [CrossRef]

23. Pokalyuk, C.; Renzette, N.; Irwin, K.K.; Pfeifer, S.P.; Gibson, L.; Britt, W.J.; Yamamoto, A.Y.; Mussi-Pinhata, M.M.; Kowalik, T.F.; Jensen, J.D. Characterizing human cytomegalovirus reinfection in congenitally infected infants: An evolutionary perspective. *Mol. Ecol.* 2017, 26, 1980–1990. [CrossRef]

24. Barbi, M.; Binda, S.; Caroppi, S.; Primace, V.; Didò, P.; Guidotti, P.; Corbetta, C.; Melotti, D. CMV gB genotypes and outcome of vertical transmission: Study on dried blood spots of congenitally infected babies. *J. Clin. Virol.* 2001, 21, 75–79. [CrossRef]

25. Murphy, E.; Shenk, T.E. *Human Cytomegalovirus Genome*; Springer: Berlin/Heidelberg, Germany, 2008; Volume 325, ISBN 9783540773481.

26. Britt, W.J.; Mach, M. Human cytomegalovirus glycoproteins. *Intervirology* 1996, 39, 401–412. [CrossRef]

27. Isaacson, M.K.; Compton, T. Human cytomegalovirus glycoprotein B is required for virus entry and cell-to-cell spread but not for virion attachment, assembly, or egress. *J. Virol.* 2009, 83, 3891–3903. [CrossRef]

28. Mach, M.; Kroppf, B.; Dal Monte, P.; Britt, W. Complex Formation by Human Cytomegalovirus Glycoproteins M (gpUL100) and N (gpUL73). *J. Virol.* 2000, 74, 11881–11892. [CrossRef]

29. Gretch, D.R.; Kari, B.; Rasmussen, L.; Gehrz, R.C.; Stinski, M.F. Identification and characterization of three distinct families of glycoprotein complexes in the envelopes of human cytomegalovirus. *J. Virol.* 1988, 62, 875–881. [CrossRef]

30. Wang, D.; Shenk, T. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. *Proc. Natl. Acad. Sci. USA* 2005, 102, 18153–18158. [CrossRef]

31. Notredame, C.; Higgins, D.G.; Heringa, J. T-coffee: A novel method for fast and accurate multiple sequence alignment. *J. Mol. Biol.* 2000, 302, 205–217. [CrossRef]

32. Chou, S. Comparative analysis of sequence variation in gp116 and gp55 components of glycoprotein B of human cytomegalovirus. *Virology* 1992, 188, 388–390. [CrossRef]

33. Chou, S. Analysis of interstrain variation in cytomegalovirus glycoprotein B sequences encoding neutralization-related epitopes. *J. Infect. Dis.* 1991, 163, 1229–1234. [CrossRef]

34. Pignatelli, S.; Dal Monte, P.; Landini, M.P. gpUL73 (gN) genomic variants of human cytomegalovirus isolates are clustered into four distinct genotypes. *J. Virol.* 2001, 82, 2777–2784. [CrossRef] [PubMed]

35. Pignatelli, S.; Dal Monte, P.; Rossini, G.; Chou, S.; Gojobori, T.; Hanada, K.; Guo, J.J.; Rawlinson, W.; Britt, W.; Mach, M.; et al. Human cytomegalovirus glycoprotein N (gpUL73-gN) genomic variants: Identification of a novel subgroup, geographical distribution and evidence of positive selective pressure. *J. Gen. Virol.* 2003, 84, 647–655. [CrossRef]

36. Paterson, D.A.; Dyer, A.P.; Milne, R.S.B.; Sevilla-Reyes, E.; Gompels, U.A. A role for human cytomegalovirus glycoprotein O (gO) in cell fusion and a new hypervariable locus. *Virology* 2002, 293, 281–294. [CrossRef]

37. Rasmussen, L.; Geissler, A.; Cowan, C.; Chase, A.; Winters, M. The genes encoding the gCIII complex of human cytomegalovirus exist in highly diverse combinations in clinical isolates. *J. Virol.* 2002, 76, 10841–10848. [CrossRef]

38. Stanton, R.; Westmoreland, D.; Fox, J.D.; Davison, A.J.; Wilkinson, G.W.G. Stability of Human cytomegalovirus genotypes in transplant patients over time. *J. Infect. Dis.* 2001, 188, 2275–2279. [CrossRef] [PubMed]

39. Mattick, C.; Dewin, D.; Polley, S.; Sevilla-Reyes, E.; Pignatelli, S.; Rawlinson, W.; Wilkinson, G.; Dal Monte, P.; Gompels, U.A. Linkage of human cytomegalovirus glycoprotein gO variant groups identified from worldwide clinical isolates with gN genotypes, implications for disease associations and evidence for N-terminal sites of positive selection. *Virology* 2004, 318, 582–597. [CrossRef]

40. Görzer, I.; Guelly, C.; Trajanoski, S.; Puchhammer-Stöckl, E. Deep sequencing reveals highly complex dynamics of human cytomegalovirus genotypes in transplant patients over time. *J. Virol.* 2010, 84, 7195–7203. [CrossRef]

41. Renzette, N.; Kowalik, T.F.; Jensen, J.D. On the relative roles of background selection and genetic hitchhiking in shaping human cytomegalovirus genetic diversity. *Mol. Ecol.* 2016, 25, 403–413. [CrossRef]

42. Murthy, S.; Hayward, G.S.; Wheelan, S.; Forman, M.S.; Ahn, J.H.; Pass, R.F.; Arav-Boger, R. Detection of a single identical cytomegalovirus (CMV) strain in recently seroconverted young women. *PLoS ONE* 2011, 6, e15949. [CrossRef]

43. Yan, H.; Koyano, S.; Inami, Y.; Yamamoto, Y.; Suzutani, T.; Mizuguchi, M.; Ushijima, H.; Kurane, I.; Inoue, N. Genetic linkage among human cytomegalovirus glycoprotein N (gN) and gO genes, with evidence for recombination from congenitally and post-natally infected Japanese infants. *J. Gen. Virol.* 2008, 89, 2275–2279. [CrossRef]

44. Arav-Boger, R. Strain variation and disease severity in congenital cytomegalovirus infection: In search of a viral marker. *Infect. Dis. Clin. N. Am.* 2015, 29, 401–414. [CrossRef] [PubMed]

45. Klein, M.; Schoppel, K.; Amvrossiadi, N.; Mach, M. Strain-specific neutralization of human cytomegalovirus isolates by human sera. *J. Virol.* 1999, 73, 878–886. [CrossRef]

46. Cui, X.; Freed, D.C.; Wang, D.; Qiu, P.; Li, F.; Fu, T-M.; Kauvar, L.M.; McVoy, M.A. Impact of antibodies and strain polymorphisms on cytomegalovirus entry and spread in fibroblasts and epithelial cells. *J. Virol.* 2017, 91, 1–17. [CrossRef]
Viruses 2021, 13, 1106

48. Beninga, J.; Kalbacher, H.; Mach, M. Analysis of T helper cell response to glycoprotein H (gpUL75) of human cytomegalovirus: Evidence for strain-specific T cell determinants. J. Infect. Dis. 1996, 173, 1051–1061. [CrossRef]

49. Burke, H.G.; Heldwein, E.E. Crystal structure of the human cytomegalovirus glycoprotein B. PLoS Pathog. 2015, 11, e1005227. [CrossRef]

50. Chandramouli, S.; Ciferri, C.; Nikitin, P.A.; Caló, S.; Gerrein, R.; Balabanis, K.; Monroe, J.; Heberer, C.; Lilja, A.E.; Settembre, E.C.; et al. Structure of HCMV glycoprotein B in the postfusion conformation bound to a neutralizing human antibody. Nat. Commun. 2015, 6, 8176. [CrossRef]

51. Bagdonaite, I.; Nordén, R.; Joshi, H.J.; King, S.L.; Vakhrushev, S.Y.; Olofsson, S.; Wandall, H.H. Global mapping of O-glycosylation of varicella zoster virus, human cytomegalovirus, and Epstein-Barr virus. J. Biol. Chem. 2016, 291, 12014–12028. [CrossRef]

52. Spaete, R.R.; Thayer, R.M.; Probert, W.S.; Masiarz, F.R.; Chamberlain, S.H.; Rasmussen, L.; Merigan, T.C.; Pachl, C. Human cytomegalovirus strain Towne glycoprotein B is processed by proteolytic cleavage. Virology 1988, 167, 207–225. [CrossRef]

53. Haberland, M.; Meyer-König, U.; Hufert, F.T. Variation within the glycoprotein B gene of human cytomegalovirus is due to homologous recombination. J. Gen. Virol. 1999, 80, 1495–1500. [CrossRef]

54. Fan, J.; Zhang, X.; Chen, X.M.; Gao, H.N.; Yang, M.F.; Zhao, H.; Hu, J.H.; Ma, W.H. Monitoring of human cytomegalovirus glycoprotein B genotypes using real-time quantitative PCR in immunocompromised Chinese patients. J. Virol. Methods 2009, 160, 74–77. [CrossRef]

55. Grosjean, J.; Hantz, S.; Cotin, S.; Baclet, M.C.; Mengelle, C.; Trapes, L.; Virey, B.; Undreiner, F.; Brosset, P.; Pasquier, C.; et al. Direct genotyping of cytomegalovirus envelope glycoproteins from toddler’s saliva samples. J. Clin. Virol. 2009, 46, 43–48. [CrossRef] [PubMed]

56. Zhang, X.; Huang, Y.P.; Gao, H.N.; Yang, M.F.; Zhao, H.; Hu, J.H.; Chen, X.M.; Ma, W.H.; Fan, J. Quantification of cytomegalovirus glycoprotein Bn DNA in hematopoietic stem cell transplant recipients by real-time PCR. PLoS ONE 2012, 7, e51224. [CrossRef] [PubMed]

57. Meyer-König, U.; Haberland, M.; Von Laer, D.; Haller, O.; Hufert, F.T. Variation within the glycoprotein B gene of human cytomegalovirus is due to homologous recombination. J. Infect. Dis. 1998, 177, 1162–1169. [CrossRef] [PubMed]

58. Rasmussen, L.; Hong, C.; Zipeto, D.; Morris, S.; Sherman, D.; Chou, S.; Miner, R.; Drew, W.L.; Wolitz, R.; Dowling, A.; et al. Cytomegalovirus gB genotype distribution differs in human immunodeficiency virus-infected patients and immunocompromised allograft recipients. J. Infect. Dis. 1997, 175, 179–184. [CrossRef]

59. Peak, R.; Verbraak, F.; Bruinenberg, M.; Van Der Leij, A.; Van Der Horn, G.; Kijlstra, A. Cytomegalovirus glycoprotein B genotyping in ocular fluids and blood of AIDS patients with cytomegalovirus retinitis. Invest. Ophthalmol. Vis. Sci. 1998, 39, 1183–1187.

60. Wada, K.; Mizuno, S.; Kato, K.; Kamiya, T.; Ozawa, K. Cytomegalovirus glycoprotein B sequence variation among Japanese bone marrow transplant recipients. Intervirology 1997, 40, 215–219. [CrossRef]

61. Pacsa, A.S.; Essa, S.; Voevodin, A.; El-Shazly, A.; Kazak, H.; Nampoori, M.R.N.; Johny, K.V.; Said, T.; Al-Nakib, W. Correlation between CMV genotypes, multiple infections with herpesviruses (HHV-6, 7) and development of CMV disease in kidney recipients in Kuwait. FEMS Immunol. Med. Microbiol. 2003, 35, 125–130. [CrossRef]

62. Tanaka, K.; Numazaki, K.; Tsutsumi, H. Human cytomegalovirus genetic variability in strains isolated from Japanese children during 1983–2003. J. Med. Virol. 2005, 76, 356–360. [CrossRef]

63. Yu, Z.S.; Zou, C.C.; Zheng, J.Y.; Zhao, Z.Y. Cytomegalovirus gB genotype and clinical features in Chinese infants with congenital infections. Intervirology 2006, 49, 281–285. [CrossRef] [PubMed]

64. Jin, H.; Wang, X.; Li, S. Human cytomegalovirus glycoprotein B genotype correlates with different symptoms of infected infants. Intervirology 2007, 50, 219–223. [CrossRef] [PubMed]

65. Yan, H.; Koyano, S.; Inami, Y.; Yamamoto, Y.; Suzutani, T.; Mizuguchi, M.; Ushijima, H.; Kurane, I.; Inoue, N. Genetic variations in the gB, UL144 and UL149 genes of human cytomegalovirus strains collected from congenitally and postnatally infected Japanese children. Arch. Virol. 2008, 153, 667–674. [CrossRef] [PubMed]

66. Qian, H.L.; Cai, T.; Jin, H.M. Human cytomegalovirus glycoprotein B genotypes in the genital tract tissue of tubal pregnancy patients. J. Int. Med. Res. 2009, 37, 385–391. [CrossRef]

67. Mewara, A.; Mishra, B.; Ratho, R.K.; Kumar, P. Cytomegalovirus glycoprotein B gene polymorphism and its association with clinical presentations in infants. Southeast Asian J. Trop. Med. Public Health 2009, 40, 759–764.

68. Shen, Z.; Shang, S.Q.; Zou, C.C.; Zheng, J.Y.; Yu, Z.S. The detection and clinical features of human cytomegalovirus infection in infants. Fetal Pediatr. Pathol. 2010, 29, 393–400. [CrossRef]

69. Gandhoke, I.; Hussain, S.A.; Chauhan, L.S.; Khare, S. Glycoprotein B genotyping in congenital/perinatal cytomegalovirus infection in symptomatic infants. Indian Pediatr. 2013, 50, 663–667. [CrossRef]

70. Paca-Uccarertkun, S.; Hiatt, R.; Leecharoen, R.; Tan-Ariya, P.; Munthrin, M.; Pongphong, S. Human cytomegalovirus gB1 genotypes among children who live at the Phayathai Babies’ home in Nonthaburi, Thailand. Southeast Asian J. Trop. Med. Public Health 2013, 44, 636–640.

71. Ding, Z.Y.; Xu, F.; Chen, D.Z.; Meng, X.N.; Xu, T.S.; Lu, M.D.; Zhuge, H.X. A multifactorial analysis of the pregnancy outcomes in cytomegalovirus-infected women. Gynecol. Obstet. Investig. 2015, 80, 106–112. [CrossRef]

72. Zhou, L.; Fan, J.; Zheng, S.S.; Ma, W.H. Genetic variation within the glycoprotein B and H genes of human cytomegalovirus in solid organ transplant recipients. Transpl. Infect. Dis. 2007, 9, 73–77. [CrossRef]
73. Mujtaba, G.; Khurshid, A.; Sharif, S.; Alam, M.M.; Aamir, U.B.; Shaukat, S.; Angez, M.; Rana, M.S.; Umair, M.; Shah, A.A.; et al. Distribution of cytomegalovirus genotypes among neonates born to infected mothers in Islamabad, Pakistan. *PLoS ONE* **2016**, *11*, e156049. [CrossRef] [PubMed]

74. Chen, J.Y.; Zheng, T.L.; Zhou, T.; Hu, P.W.; Huang, M.J.; Xu, X.; Pei, X.F. Human cytomegalovirus prevalence and distribution of glycoprotein B, O genotypes among hospitalized children with respiratory infections in West China, 2009–2014. *Trop. Med. Int. Health* **2016**, *21*, 1428–1434. [CrossRef]

75. Sarkar, A.; Das, D.; Ansari, S.; Chatterjee, R.P.; Mishra, L.; Basu, B.; Ghosh, S.K.; Bhattacharyar, M.; Chakraborty, N. Genotypes of glycoprotein B gene among the Indian symptomatic neonates with congenital CMV infection. *BMC Pediatr.* **2019**, *19*, 1–12. [CrossRef]

76. Alwan, S.N.; Shamran, H.A.; Ghailb, A.H.; Kadhim, H.S.; Al-Mayah, Q.S.; Al-Saffar, A.J.; Bayati, A.H.; Arif, H.S.; Fu, J.; Wickes, B.L. Genotyping of cytomegalovirus from symptomatic infected neonates in Iraq. *Am. J. Trop. Med. Hgy.* **2019**, *100*, 957–963. [CrossRef]

77. Min, X.; Wang, L.; Cui, A.; Zhang, C.; Wang, D.; Liu, Y.; Li, Z.; Xu, W. The nucleic acid positive rate and genotype distribution of human cytomegalovirus in human milk banks in China. *Arch. Virol.* **2020**, *165*, 1099–1107. [CrossRef]

78. Dong, N.; Cao, L.; Su, L.; Lu, L.; Dong, Z.; Xu, M.; Xu, J. Human cytomegalovirus envelope glycoprotein B, H, and N polymorphisms among infants of Shanghai area in China. *J. Med. Virol.* **2020**, *92*, 3674–3681. [CrossRef]

79. Woo, P.C.Y.; Lo, C.Y.; Lo, S.K.F.; Siu, H.; Peiris, J.S.M; Wong, S.S.Y.; Luk, W.K.; Chan, T.M.; Lim, W.W.; Yuen, K.Y. Distinct genotypic distributions of cytomegalovirus (CMV) envelope glycoprotein in bone marrow and renal transplant recipients with CMV disease. *Clin. Diagn. Lab. Immunol.* **1997**, *4*, 515–518. [CrossRef]

80. Madhaven, H.N.; Priya, K. Polymerase chain reaction based restriction fragment length polymorphism for the genotyping of cytomegalovirus (CMV) from patients with CMV disease in Chennai. *Indian J. Med. Res.* **2002**, *130*, 556.

81. Wu, Y.M.; Yan, J.; Ojuicius, D.M.; Chen, L.L.; Gu, Z.Y.; Pan, J.P. Correlation between infections with different genotypes of human cytomegalovirus and Epstein-Barr virus in subgingival samples and periodontal status of patients. *J. Clin. Microbiol.* **2007**, *45*, 3665–3670. [CrossRef]

82. Bhattarakosol, P.; Chantaraarphonkun, S. Prevalence of human cytomegalovirus (HCMV) gB genotypes in Thai patients. *Southeast Asian J. Trop. Med. Public Health* **2007**, *38*, 835–840. [PubMed]

83. Pang, X.; Humar, A.; Preiksaitis, J.K. Concurrent genotyping and quantitation of cytomegalovirus gB genotypes in solid-organ-transplant recipients by use of a real-time PCR assay. *J. Clin. Microbiol.* **2008**, *46*, 4004–4010. [CrossRef]

84. Chantaraarphonkun, S.; Bhattarakosol, P. Intra- and Intergenotypic variations among human cytomegalovirus gB genotypes. *Intervirology* **2007**, *50*, 835–840. [PubMed]

85. Yu, Z.S.; Tang, L.F.; Zou, C.C.; Zheng, J.Y.; Zhao, Z.Y. Cytomegalovirus-associated idiopathic thrombocytopenic purpura in Chinese children. *Scand. J. Infect. Dis.* **2008**, *40*, 922–927. [CrossRef]

86. Wu, K.G.; Hung, M.C.; Chang, Y.T.; Chen, C.J.; Yang, S.P.; Liu, C.Y.; Ho, D.M.T.; Chan, Y.J. Occurrence of human cytomegalovirus glycoprotein B genotypes in immunocompetent and immunosuppressed Taiwanese patients. *Intervirology* **2011**, *54*, 196–201. [CrossRef] [PubMed]

87. Tang, N.; Li, J.W.; Liu, Y.M.; Zhong, H.; Wang, L.M.; Deng, F.M.; Qu, Y.Y.; Hui, J.; Cheng, J.; Tang, B.; et al. Human cytomegalovirus infection is associated with essential hypertension in Kazakh and Han Chinese populations. *Med. Sci. Monit.* **2014**, *20*, 2508–2519. [CrossRef] [PubMed]

88. Taherkhani, R.; Farshadpour, F.; Makvandi, M.; Hamidifard, M.; Esmailizadeh, M.; Ahmadi, B.; Heidari, H. Determination of cytomegalovirus prevalence and glycoprotein B genotypes among ulcerative colitis patients in Ahvaz, Iran. *Jundishapur J. Microbiol.* **2015**, *8*, [CrossRef] [PubMed]

89. Oka, N.; Suzuki, T.; Inoue, T.; Kobayashi, T.; Ohashi, Y. Polymorphisms in cytomegalovirus genotype in immunocompetent patients with corneal endothelitis or iridocyclitis. *J. Med. Virol.* **2015**, *87*, 1441–1445. [CrossRef]

90. Eran Daglar, D.; Öngüt, G.; Colak, D.; Özkul, A.; Mutlu, D.; Zeytenoğlu, A.; Midilli, K.; Gökahmetoğlu, S.; Günseren, F.; Öğünç, D.; et al. Determination of cytomegalovirus glycoprotein B genotypes in different geographical regions and different patient groups in Turkey. *Mikrobiyol. Bul.* **2016**, *50*, 53–62. [CrossRef]

91. Hu, H.; Cheng, Y.; Peng, Q.; Chen, K. Clinical features, treatment courses, and distribution of cytomegalovirus genotypes among thrombocytopenia patients aged younger than 12 months. *Am. J. Perinatal*. **2020**, *1*, [CrossRef]

92. Nahar, S.; Hokama, A.; Iraha, A.; Ohira, T.; Kinjo, T.; Hirata, T.; Kinjo, T.; Parrott, G.L.; Fujita, J. Distribution of cytomegalovirus genotypes among ulcerative colitis patients in Okinawa, Japan. *Intest. Res.* **2018**, *16*, 90–98. [CrossRef]

93. Mohamed, H.T.; El-Shinawi, M.; Nooh, M.A.; Bashtar, A.R.; Elsayed, E.T.; Schneider, R.J.; Mohamed, M.M. Inflammatory breast cancer: High incidence of detection of mixed human cytomegalovirus genotypes associated with disease pathogenesis. *Front. Oncol.* **2014**, *4*, 246. [CrossRef]

94. Wu, X.; Wang, Y.; Xu, Y.; Wu, D.; Sun, A.; Zhu, Z.; Han, Y.; Qiu, H.; Tang, X.; Fu, Z.; et al. Cytomegalovirus glycoprotein B genotype in hematopoietic stem cell transplant patients from China. *Biol. Blood Marrow Transplant.* **2010**, *16*, 647–652. [CrossRef]

95. Madi, N.; Al-Nakib, W.; Pacsa, A.; Saeed, T. Cytomegalovirus genotypes gB1 and gH Are the most predominant genotypes among renal transplant recipients in Kuwait. *Transplant. Proc.* **2011**, *43*, 1634–1637. [CrossRef]

96. Xia, C.S.; Zhao, X.T.; Sun, Y.Y.; Zhang, Z. Human cytomegalovirus glycoprotein B genotypes in Chinese hematopoietic stem cell transplant recipients. *Intervirology* **2012**, *55*, 342–348. [CrossRef]
97. Soleimani, A.R.; Jafari, M.; Piroozmand, A.; Nikoueinejad, H.; Akbari, H.; Einollahi, B. The Incidence of Cytomegalovirus Glycoprotein B Genotypes in Kidney Transplant Recipients in Iran. Int. J. Organ Transplant. Med. 2018, 9, 173–177. [PubMed]

98. Jiang, X.J.; Zhang, J.; Xiong, Y.; Jahn, G.; Xiong, H.R.; Yang, Z.Q.; Liu, Y.Y. Human cytomegalovirus glycoprotein polymorphisms and increasing viral load in AIDS patients. PLoS ONE 2017, 12, e0176160. [CrossRef] [PubMed]

99. Terabe, K.; Sugiyama, K.; Goto, K.; Mizutani, F.; Wada, Y.; Yokoyama, T.; Ando, Y. Relationship between human cytomegalovirus glycoprotein B genotype and serum alanine aminotransferase elevation in infants. Tohoku J. Exp. Med. 2004, 203, 339–344. [CrossRef]

100. Torok-Storb, B.; Boeckh, M.; Hoy, C.; Leisenring, W.; Myerson, D.; Gooley, T. Association of specific cytomegalovirus genotypes with death from myelosuppression after marrow transplantation. Blood 1997, 90, 2097–2102. [CrossRef] [PubMed]

101. White, J.L.; Patel, E.U.; Abraham, A.G.; Grabowski, M.D.; Boppana, S. Genotypic diversity and mixed genotype distribution of urinary cytomegalovirus (CMV) shedding among CMV-seropositive children and adolescents in the United States. Open Forum Infect. Dis. 2019, 6. [CrossRef] [PubMed]

102. Sarcinella, I.; Mazzulli, T.; Willey, B.; Humar, A. Cytomegalovirus glycoprotein B genotype does not correlate with outcomes in liver transplant patients. J. Clin. Virol. 2002, 24, 99–105. [CrossRef]

103. Drew, W.L.; Chou, S.; Miner, R.C.; Mohr, B.A.; Busch, M.P.; van der Horst, C.M.; Asmuth, D.M.; Kalish, L.A. Cytomegalovirus glycoprotein B genotype distribution in Mexican children undergoing allogeneic bone marrow transplantation. J. Infect. Dis. 2002, 186, 114–117. [CrossRef]

104. Bale, J.F.; Murphy, J.R.; Demmler, G.J.; Dawson, J.; Miller, J.E.; Petheram, S.J. Intrauterine cytomegalovirus infection and glycoprotein B genotypes. J. Infect. Dis. 2000, 182, 932–936. [CrossRef] [PubMed]

105. Pati, S.K.; Pininti, S.; Novak, Z.; Chowdhury, N.; Patho, R.K.; Fowler, K.; Ross, S.; Boppana, S. Genotypic diversity and mixed infection in newborn disease and hearing loss in congenital cytomegalovirus infection. Pediatr. Infect. Dis. J. 2013, 32, 1050–1054. [CrossRef] [PubMed]

106. Aquino, V.H.; Figueiredo, L.T.M. High prevalence of renal transplant recipients infected with more than one cytomegalovirus glycoprotein B genotype. J. Med. Virol. 2000, 61, 138–142. [CrossRef]

107. Correia-Silva, J.F.; Resende, R.G.; Arão, T.C.; Abreu, M.; Teixeira, M.M.; Bittencourt, H.; Silva, T.A.; Gomez, R.S. HCMV gB genotype and its association with cytokine levels in hematopoietic stem cell transplantation. Oral Dis. 2011, 17, 530–537. [CrossRef] [PubMed]

108. González-Ramírez, J.; Uribe-Gutierrez, G.; Jiménez-Hernandez, E.; Velázquez-Guadarrama, N.; Bello-González, A.; Vazquez-Meraz, E.; Arellano-Galindo, J. Cytomegalovirus gB genotype distribution in Mexican children undergoing allogeneic bone marrow transplantation. Intervirology 2012, 55, 318–320. [CrossRef]
Viruses 2021, 13, 1106

120. Vilas Boas, L.S.; De Souza, V.A.U.F.; De Oliveira, A.C.P.; Rodriguez Viso, A.T.; Nascimento Filho, A.M.; Nascimento, M.C.; Pannuti, C.S. Cytomegalovirus glycoprotein B genotypes and central nervous system disease in AIDS patients. J. Med. Virol. 2003, 71, 404–407. [CrossRef]

121. Cunha, A.A.; Aquino, V.H.; Mariguela, V.; Nogueira, M.L.; Figueiredo, L.T.M. Evaluation of glycoprotein B genotypes and load of CMV infecting blood leukocytes of AIDS patients. Rev. Inst. Med. Trop. Sao Paulo 2011, 53, 83–88. [CrossRef]

122. Arellano-Galindo, J.; Villanueva-Garcia, D.; Cruz-Ramirez, J.L.; Yalaupari-Meja, J.P.; Uribe-Gutierrez, G.; Velazquez-Guadarrama, N.; Nava-Frias, M.; Muñoz-Hernández, O.; Mejia-Aranguré, J.M. Detection and gB genotyping of CMV in Mexican preterm infants in the context of maternal seropositivity. J. Infect. Dev. Ctries. 2014, 8, 758–767. [CrossRef]

123. Gonzalez-Sanchez, H.M.; Alvarado-Hernandez, D.L.; Guerrera-Palomares, S.; Garcia-Sepulveda, C.A.; Noyola, D.E. Cytomegalovirus gB genotype B in Mexican children and women. Interiervirology 2015, 58, 115–121. [CrossRef]

124. Barrado, L.; Prieto, C.; Hernando, S.; Folguere, L. Detection of glycoproteins B and H genotypes to predict the development of Cytomegalovirus disease in solid organ transplant recipients. J. Clin. Virol. 2018, 109, 50–56. [CrossRef] [PubMed]

125. Ciotti, M.; Cellà, E.; Ritò, M.; Ciccozo, M.; Cavallo, R.; Perno, C.F.; Costa, C. Cytomegalovirus gB genotype distribution in Italian transplant patients. Interiervirology 2018, 60, 165–170. [CrossRef] [PubMed]

126. Janković, M.; Cupić, M.; Knežević, A.; Vujić, D.; Soldatović, I.; Zečević, Ž.; Gebeljić, B.; Jovanović, T. Cytomegalovirus glycoprotein B and N genotypes in pediatric recipients of the hematopoietic stem cell transplant. Virology 2020, 548, 168–173. [CrossRef] [PubMed]

127. Fidouh-Houhou, N.; Duval, X.; Bissuel, F.; Bourbonnais, V.; Flandre, P.; Jordan, M.C.; Villeda, P.; Geissler, B.; Chauviere, I.; Lebon, M.; Belhassen, B.; et al. Distribution of UL73 genotypes in congenital cytomegalovirus infection. Virol. J. 2017, 14, 102. [CrossRef] [PubMed]

128. Goossens, V.J.; Wolffs, P.F.; Van Loo, I.H.; Bruggeman, C.A.; Verbon, A. CMV DNA levels and CMV gB subtypes in ART-naive patients with congenital cytomegalovirus infection. PLoS ONE 2016, 11, e0159154. [CrossRef] [PubMed]

129. Tarragona, E.; Studzinska, M.; Nowakowska, D.; Wilczyński, J.; Rycel, M.; Suski, P.; Gaj, Z.; Kaczmarek, B.; Zbigniew, Z.; Leśniokowski, Z.J. Distribution of UL144, US28 and UL55 genotypes in Polish newborns with congenital cytomegalovirus infection. Przegl. Epidemiol. 2011, 65, 165–170. [CrossRef] [PubMed]

130. Vogel, J.U.; Otte, J.; Koch, F.; Gumbel, H.; Doerr, H.W.; Cinatl, J. Role of human cytomegalovirus genotype polymorphisms in congenital infections in South Hungary. Aids 2009, 23, 1425–1429. [CrossRef]

131. Lukacsi, A.; Tarodi, B.; Endreffy, E.; Babinszki, A.; Pal, A.; Pusztai, R. Human cytomegalovirus gB genotype 1 is dominant in congenital infections. Med. Microbiol. Immunol. 2013, 202, 37–47. [CrossRef]

132. Picone, O.; Costa, J.M.; Lerner-Ville, M.; Ermault, P.; Olivi, M.; Ville, Y. Cytomegalovirus (CMV) glycoprotein B genotype and CMV DNA load in the amniotic fluid of infected fetuses. Prenat. Diagn. 2004, 24, 1001–1006. [CrossRef]

133. Grosjean, J.; Trapes, L.; Hantz, S.; Mengelle, C.; Virey, B.; Undreiner, F.; Messager, V.; Denis, F.; Marin, B.; Alain, S. Human cytomegalovirus quantification in toddlers saliva from day care centers and emergency unit: A feasibility study. J. Clin. Virol. 2014, 61, 371–377. [CrossRef]

134. Zawilinska, B.; Szostek, S.; Kopeć, J.; Koprynia, M.; Kosz-Vnencak, M. UL55 genotype diversity of cytomegalovirus strains isolated from newborns and infants hospitalized in southern Poland. Przegląd Epidemiol. 2011, 65, 409–413. [CrossRef]

135. Paradowska, E.; Studzińska, M.; Nowakowska, D.; Wilczyński, J.; Rycel, M.; Suski, P.; Gaj, Z.; Kazcmarek, B.; Zbrog, Z.; Lesniskowski, Z.J. Distribution of UL144, US28 and UL55 genotypes in Polish newborns with congenital cytomegalovirus infections. Eur. J. Clin. Microbiol. Infect. Dis. 2012, 31, 1335–1345. [CrossRef] [PubMed]

136. Nijman, J.; Mandemaker, F.S.; Verboon-Maciolek, M.A.; Aitken, S.C.; Van Loon, A.M.; De Vries, L.S.; Schuurman, R. Genotype distribution in Italian transplant patients. J. Clin. Virol. 2018, 101, 1001–1006. [CrossRef]

137. Puhakka, L.; Patti, S.; Lappalainen, M.; Lönnqvist, T.; Niemensivu, R.; Lindahl, P.; Nieminen, T.; Seuri, R.; Numponen, I.; Boppana, S.; et al. Viral shedding, and distribution of cytomegalovirus glycoprotein B (UL75), gB and gN types with symptomatic disease. Open Forum Infect. Dis. 2015, 2, 2633851. [CrossRef]

138. Kadambari, S.; Atkinson, C.; Luck, S.; Macnary, M.; Conibear, T.; Harrison, I.; Booth, C.; Sharland, M.; Griffiths, D.P. Characterising variation in five genetic loci of cytomegalovirus during treatment for congenital infection. J. Clin. Med. 2017, 89, 502–507. [CrossRef]

139. Puhakka, L.; Patti, S.; Lappalainen, M.; Lönnqvist, T.; Niemensivu, R.; Lindahl, P.; Nieminen, T.; Seuri, R.; Numponen, I.; Boppana, S.; et al. Viral shedding, and distribution of cytomegalovirus glycoprotein B (UL75), gB and gN types with symptomatic disease. J. Clin. Virol. 2020, 125, 104287. [CrossRef]
Viruses 2021, 13, 1106

143. Arista, S.; De Grazia, S.; Giammanco, G.M.; Di Carlo, P.; Iannitto, E. Human cytomegalovirus glycoprotein B genotypes in immunocompetent, immunocompromised, and congenitally infected Italian populations. *Arch. Virol.* 2003, 148, 547–554. [CrossRef] [PubMed]

144. Coaquette, A.; Bourgeois, A.; Dirand, C.; Varin, A.; Chen, W.; Herbein, G. Mixed cytomegalovirus glycoprotein B genotypes in immunocompromised patients. *Clin. Infect. Dis.* 2004, 39, 155–161. [CrossRef] [PubMed]

145. Görzer, I.; Kerschner, H.; Redlberger-Fritz, M.; Puchhammer-Stöckl, E. Human cytomegalovirus (HCMV) genotype populations in immunocompetent individuals during primary HCMV infection. *J. Clin. Virol.* 2010, 48, 100–103. [CrossRef] [PubMed]

146. Bergallo, M.; Costa, C.; Gambarino, S.; Tornicelli, A.; Astegiano, S.; Terlizzi, M.E.; Solidoro, P.; Cavallo, R. Human cytomegalovirus glycoprotein B genotyping from bronchoalveolar lavage specimens. *Can. J. Microbiol.* 2011, 57, 273–277. [CrossRef]

147. Jakovljevic, A.; Andric, M.; Knezevic, A.; Soldatovic, I.; Nikolic, N.; Karalic, D.; Milasin, J. Human cytomegalovirus and Epstein-Barr virus genotypes in apical periodontitis lesions. *J. Endod.* 2015, 41, 1847–1851. [CrossRef] [PubMed]

148. Fries, B.C.; Chon, S.; Boeckh, M.; Torok-Storb, B. Frequency distribution of cytomegalovirus envelope glycoprotein genotypes in bone marrow transplant recipients. *J. Infect. Dis.* 1994, 169, 769–774. [CrossRef]

149. Vogelberg, C.; Meyer-König, U.; Hufert, F.T.; Kirste, G.; Von Laer, D. Human cytomegalovirus glycoprotein B genotypes in renal transplant recipients. *J. Med. Virol.* 1996, 50, 31–34. [CrossRef]

150. Hebart, H.; Greif, M.; Krause, H.; Kanz, L.; Jahn, G.; Müller, C.A.; Einsele, H. Interstrain variation of immediate early DNA sequences and glycoprotein B genotypes in cytomegalovirus clinical isolates. *Med. Microbiol. Immunol.* 1997, 186, 135–138. [CrossRef]

151. Meyer-König, U.; Vogelberg, C.; Bongarts, A.; Kampa, D.; Delbrück, A.; Wolff-Vorbeck, G.; Kirste, G.; Haberland, M.; Hufert, F.T.; Von Laer, D. Glycoprotein B genotype correlates with cell tropism in vivo of human cytomegalovirus infection. *J. Med. Virol.* 1998, 55, 75–81. [CrossRef]

152. De Vries, J.J.C.; Wessels, E.; Korver, A.M.H.; Van Der Eijk, A.A.; Rusman, L.G.; Kroes, A.C.M.; Vossen, A.C.T.M. Rapid genotyping of cytomegalovirus in dried blood spots by multiplex real-time PCR assays targeting the envelope glycoprotein gB and gH genes. *J. Clin. Microbiol.* 2012, 50, 232–237. [CrossRef]

153. Zawilinska, B.; Szostek, S.; Kopeć, J.; Patkówśka-Jakubas, B.; Kosz-Vnenchak, M. Multiplex real-time PCR to identify a possible re-infection with different strains of human cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients. *Acta Biochim. Pol.* 2016, 63, 161–166. [CrossRef]

154. Trincado, D.E.; Scott, G.M.; White, P.A.; Hunt, C.; Rasmussen, L.; Rawlinson, W.D. Human cytomegalovirus strains associated with congenital and perinatal infections. *J. Med. Virol.* 2000, 61, 481–487. [CrossRef]

155. Cranage, M.P.; Kouzarides, T.; Bankier, A.T.; Satchwell, S.; Weston, K.; Tomlinson, P.; Barrell, B.; Hart, H.; Bell, S.E.; Minson, A.C. Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus. *EMBO J.* 1986, 5, 3057–3063. [CrossRef] [PubMed]

156. Nelson, C.S.; Huffman, T.; Jenks, J.A.; De La Rosa, E.C.; Xie, G.; Vandergrift, N.; Pass, R.F.; Pollara, J.; Permar, S.R. HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions. *Proc. Natl. Acad. Sci. USA* 2018, 115, 6267–6272. [CrossRef] [PubMed]

157. Bootz, A.; Karbach, A.; Spindler, J.; Kropff, B.; Reuter, N.; Sticht, H.; Winkler, T.H.; Britt, W.J.; Mach, M. Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus. *PLoS Pathog.* 2017, 13, e1006601. [PubMed]

158. Barnani, I.; Gomes, A.C.; Sodi, I.; Langstone, T.; Rothwell, E.; Atkinson, C.; Pichon, S.; Piras-Doucè, F.; Griffiths, P.D.; Reeves, M.B. Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation. *EBioMedicine* 2019, 50, 45–54. [CrossRef] [PubMed]

159. Bernstein, D.I.; Munoz, F.M.; Callahan, S.T.; Rupp, R.; Wootton, S.H.; Edwards, K.M.; Turley, C.B.; Stanberry, L.R.; Patel, S.M.; Mcneal, M.M.; et al. Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial. *Vaccine* 2016, 34, 313–319. [CrossRef]

160. Zhang, C.; Pass, R.F. Detection of cytomegalovirus infection during clinical trials of glycoprotein B vaccine. *Vaccine* 2004, 23, 507–510. [CrossRef]

161. Nelson, C.S.; Vera Cruz, D.; Su, M.; Xie, G.; Vandergrift, N.; Pass, R.F.; Forman, M.; Diener-West, M.; Koelle, K.; Arav-Boger, R.; et al. Intrahost dynamics of human cytomegalovirus variants acquired by seronegative glycoprotein B vaccinees. *J. Virol.* 2018, 93, 1–17. [CrossRef]

162. Tang, J.; Frascari, G.; Lebbink, R.J.; Ostermann, E.; Brune, W. Human cytomegalovirus glycoprotein B variants affect viral entry, cell fusion, and genome stability. *Proc. Natl. Acad. Sci. USA* 2019, 116, 18021–18030. [CrossRef]

163. Fogliertini, M.; Marcandalli, J.; Perez, L. HCMV envelope glycoprotein diversity demystified. *Front. Microbiol.* 2019, 10, 1005. [CrossRef]

164. Gardner, T.J.; Tortorella, D. Virion glycoprotein-mediated immune evasion by human cytomegalovirus: A sticky virus makes a slick getaway. *Microbiol. Mol. Biol. Rev.* 2016, 80, 663–677. [CrossRef] [PubMed]

165. Shimamura, M.; Mach, M.; Britt, W.J. Human cytomegalovirus infection elicits a glycoprotein M (gM)/gN-specific virus-neutralizing antibody response. *J. Virol.* 2006, 80, 4591–4600. [CrossRef] [PubMed]

166. Burkhardt, C.; Himmlein, S.; Britt, W.; Winkler, T.; Mach, M. Glycoprotein N subtypes of human cytomegalovirus induce a strain-specific antibody response during natural infection. *J. Gen. Virol.* 2009, 90, 1951–1961. [CrossRef] [PubMed]
167. Pati, S.K.; Novak, Z.; Purser, M.; Arora, N.; Mach, M.; Britt, W.J.; Boppana, S.B. Strain-specific neutralizing antibody responses against human cytomegalovirus envelope glycoprotein N. *Clin. Vaccine Immunol.* 2012, 19, 909–913. [CrossRef]

168. Zhou, M.; Lanchy, J.-M.; Ryckman, B.J. Human cytomegalovirus gH/gL promotes the fusion step of entry into all cell types, whereas gH/gL/UL128-131 broadens virus tropism through a distinct mechanism. *J. Virol.* 2015, 89, 8999–9009. [CrossRef]

169. Puchhammer-Stöckl, E.; Görzer, I.; Zoufaly, A.; Jakš, P.; Bauer, C.C.; Klepetko, W.; Popow-Kraupp, T. Emergence of multiple cytomegalovirus strains in blood and lung of lung transplant recipients. *Transplantation* 2006, 81, 187–194. [CrossRef]

170. Roubalova, K.; Strunecký, O.; Vitek, A.; Zufanova, S.; Prochazka, B. Genetic variability of cytomegalovirus glycoprotein O in hematopoietic stem cell transplant recipients. *Transpl. Infect. Dis.* 2011, 13, 237–243. [CrossRef]

171. Kalser, J.; Adler, B.; Mach, M.; Kropff, B.; Puchhammer-Stöckl, E.; Görzer, I. Differences in growth properties among two human cytomegalovirus glycoprotein O genotypes. *Front. Microbiol.* 2017, 8, 1609. [CrossRef]

172. Brait, N.; Stögerer, T.; Kalser, J.; Adler, B.; Kunz, I.; Benesch, M.; Kropff, B.; Mach, M.; Puchhammer-Stöckl, E.; Görzer, I. Influence of human cytomegalovirus glycoprotein O polymorphism on the inhibitory effect of soluble forms of trimer- and pentamer-specific entry receptors. *J. Virol.* 2020, 94, 1–17. [CrossRef]

173. Day, L.Z.; Stegmann, C.; Schultz, E.P.; Lanchy, J.-M.; Yu, Q.; Ryckman, B.J. Polymorphisms in human cytomegalovirus glycoprotein O (gO) exert epistatic influences on cell-free and cell-to-cell spread and antibody neutralization on gH epitopes. *J. Virol.* 2020, 94, e02051-19. [CrossRef]

174. Adler, B.; Scrivano, L.; Ruzcics, Z.; Rupp, B.; Sinzger, C.; Koszinowski, U. Role of human cytomegalovirus UL131A in cell type-specific virus entry and release. *J. Gen. Virol.* 2006, 87, 2451–2460. [CrossRef] [PubMed]

175. Straschewski, S.; Patrone, M.; Walther, P.; Gallina, A.; Mertens, T.; Frascaroli, G. Protein pUL128 of human cytomegalovirus Is necessary for monocyte infection and blocking of migration. *J. Virol.* 2011, 85, 5150–5158. [CrossRef] [PubMed]

176. Gerna, G.; Percivalle, E.; Lilleri, L.; Lozza, L.; Fornara, C.; Hahn, G.; Baldanti, F.; Revello, M.G. Dendritic-cell infection by human cytomegalovirus Is restricted to strains carrying functional UL131-128 genes and mediates efficient viral antigen presentation to CD8+ T cells. *J. Gen. Virol.* 2005, 86, 275–284. [CrossRef]

177. Urban, M.; Klein, M.; Britt, W.J.; Haßfurther, E.; Mach, M. Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response. *J. Gen. Virol.* 1996, 77, 1537–1547. [CrossRef]

178. Freed, D.C.; Tang, Q.; Tang, A.; Li, F.; He, X.; Huang, Z.; Meng, W.; Xia, L.; Finnefrock, A.C.; Durr, E.; et al. Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine. *Proc. Natl. Acad. Sci. USA* 2013, 110, 4997–5005. [CrossRef]

179. Ishibashi, K.; Tokumoto, T.; Tanabe, K.; Shirakawa, H.; Hashimoto, K.; Kushida, N.; Yanagida, T.; Inoue, N.; Yamaguchi, O.; Toma, H.; et al. Association of the outcome of renal transplantation with antibody response to cytomegalovirus strain–specific glycoprotein H epitopes. *Clin. Infect. Dis.* 2007, 45, 60–67. [CrossRef]

180. Li, W.; Liu, L.; Tao, R.; Zheng, X.; Li, H.; Shang, S. Epidemiological characteristics of human cytomegalovirus infection and glycoprotein H genotype in Chinese children. *Pediatr. Neonatol.* 2020, 61, 63–67. [CrossRef]

181. Li, W.; Tao, R.; Zhang, X.; Shu, Q.; Gao, H.H.; Shang, S.Q.; Peng, Z.Y.; Li, H.M. Rapid and sensitive identification of glycoprotein H genotypes in clinical human cytomegalovirus samples. *Jpn. J. Infect. Dis.* 2015, 68, 135–137. [CrossRef] [PubMed]

182. Paradowska, E.; Jabłońska, A.; Studzińska, M.; Kasztelewicz, B.; Zawilińska, B.; Wiśniewska-Ligier, M.; Dzierzanowska-Fangrat, K.; Woźniakowska-Gęsicka, T.; Kosz-Vnenchak, M.; Leśnikowski, Z.J. Cytomegalovirus glycoprotein H genotype distribution and the relationship with hearing loss in children. *J. Med. Virol.* 2014, 86, 1421–1427. [CrossRef]

183. Paradowska, E.; Jabłońska, A.; Studzińska, M.; Kasztelewicz, B.; Wiśniewska-Ligier, M.; Dzierzanowska-Fangrat, K.; Woźniakowska-Gęsicka, T.; Czech-Kowalska, J. Distribution of the CMV glycoprotein gH/gL/gO and gH/gL/UL128/UL130/UL131A complex variants and associated clinical manifestations in infants infected congenitally or postnatally. *Sci. Rep.* 2019, 9, 1–15. [CrossRef] [PubMed]